Clinical trials: Pulmonary Neoplasm
Malignant Pleural Effusion, Stage IIIB Non-small Cell Lung Cancer
FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
This phase II trial studies how well fludeoxyglucose F 18 (FDG)-labeled positron emission tomography (PET) scan works in planning chemotherapy in treating patients with stage IIIB or IV non-small cell lung cancer (NSCLC).
- Conditions
- Malignant Pleural Effusion, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00564733
- Testing
- carboplatin, docetaxel, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- University of Washington
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer
This phase II trial studies how well pembrolizumab works in treating patients with non-squamous non-small cell lung cancer which has spread to other places in the body.
- Trial name
- NCT02955758
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Joel Neal
Non-Small Cell Lung Cancer
A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.
The main purpose of the study is to learn about the effectiveness and treatment sequence of lung cancer medicines. This study is performed outside of clinical trials in Norway in patients with metastatic non-small cell lung…
- Trial name
- DELINOR (NCT05834348)
- Testing
- lorlatinib, crizotinib, brigatinib
- Where
- Norway
- Volunteers
- 5,279 people
- Sponsor
- Pfizer
Lungcancer
A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung
MEK162 has shown significant inhibition of tumor growth as a single agent in NSCLC xenograft models in mice and human cancer cells in vitro, which have KRAS and/or other mutations.
- Trial name
- MEK162 (NCT02185690)
- Testing
- Binimetinib, Pemetrexed, Carboplatin
- Where
- 4 sites in Canada
- Volunteers
- 13 people
- Sponsor
- University Health Network, Toronto
Non-Small Cell Lung Cancer, Renal Cell Carcinoma
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
The purpose of this study is to evaluate participant preference for coformulated hyaluronidase/pembrolizumab pembrolizumab (+) berahyaluronidase alfa [MK-3475A] administered subcutaneously (SC) over pembrolizumab [MK-3475]…
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma
- Trial name
- NCT06099782
- Testing
- Pembrolizumab (+) Berahyaluronidase alfa, Pembrolizumab
- Where
- 45 sites in United States, Argentina and 8 more
- Volunteers
- 147 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Non Small Cell Lung
Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy of vorinostat and bortezomib in the third line treatment of advanced NSCLC, as well as to assess toxicity (including neuropathy) and tolerability of this regimen.
- Trial name
- NCT00798720
- Testing
- vorinostat, bortezomib
- Volunteers
- 18 people
- Sponsor
- University of Wisconsin, Madison
Malignant Pleural Mesothelioma
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
This research is being done to find out if pemetrexed and cisplatin work better when given together with an experimental drug called MORAb-009 in patients with malignant pleural mesothelioma.
- Trial name
- Amatuximab (NCT00738582)
- Testing
- MORAb-009 (Amatuximab), Pemetrexed, Cisplatin
- Where
- 28 sites in United States, Canada and 3 more
- Volunteers
- 89 people
- Sponsor
- Morphotek
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
To assess the efficacy and safety of AZD9291 versus a standard of care epidermal growth factor receptor tyrosine kinase inhibitor in patients with locally advanced or Metastatic Non Small Cell Lung Cancer
- Trial name
- FLAURA (NCT02296125)
- Testing
- Erlotinib 150/100 mg, Gefitinib 250 mg
- Where
- 170 sites in United States, Australia and 28 more
- Volunteers
- 674 people
- Sponsor
- AstraZeneca
Colorectal Neoplasm, Head and Neck Neoplasm
Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED)
This study is proposed to evaluate the efficacy and safety of temozolomide, an oral anti-cancer agent, in a participant population selected for a biomarker.
- Conditions
- Colorectal Neoplasm, Head and Neck Neoplasm, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasm
- Trial name
- NCT00423150
- Testing
- Temozolomide
- Volunteers
- 86 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer
superDimension™ Navigation System Version 7.2 With Fluoroscopic Navigation Technology
The purpose of this investigation is to confirm the clinical accuracy of the superDimension™ Navigation System Version 7.2 with Fluoroscopic Navigation Technology.
- Trial name
- NCT03585959
- Testing
- superDimension™ Navigation System Version 7.2
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Medtronic - MITG
Extensive Stage Small Cell Lung Carcinoma, Recurrent Small Cell Lung Carcinoma
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage
This randomized phase II trial studies cisplatin and etoposide to see how well they work when given with or without Hedgehog inhibitor GDC-0449 (vismodegib) or IGF-1R MOAB IMC-A12 (cixutumumab) in treating patients with…
- Trial name
- NCT00887159
- Testing
- Cisplatin, Cixutumumab, Etoposide
- Where
- 301 sites in United States
- Volunteers
- 168 people
- Sponsor
- National Cancer Institute (NCI)
Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT)
Cancer Venous Thromboembolism (VTE)
The primary objective is to demonstrate the non-inferiority of edoxaban (preceded by a short course of LMWH) compared with dalteparin for the prevention of the combined outcome of recurrent venous thromboembolism (VTE) or major…
- Conditions
- Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Cancer
- Trial name
- NCT02073682
- Testing
- Edoxaban, Dalteparin, Low molecular weight heparin
- Where
- 9 sites in United States, Belgium and 4 more
- Volunteers
- 1,046 people
- Sponsor
- Daiichi Sankyo
Non-small Cell Lung Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
This trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy (NAC) before surgery [neoadjuvant phase], followed by pembrolizumab alone after surgery…
- Trial name
- NCT03425643
- Testing
- Pembrolizumab, Cisplatin, Gemcitabine
- Where
- 227 sites in United States, Argentina and 23 more
- Volunteers
- 797 people
- Sponsor
- Merck Sharp & Dohme LLC
Malignant Mesothelioma
S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well everolimus works in treating patients with pleural malignant…
- Trial name
- NCT00770120
- Testing
- everolimus
- Where
- 129 sites in United States
- Volunteers
- 61 people
- Sponsor
- SWOG Cancer Research Network
Non-Small Cell Lung Cancer
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
This is a Phase III, randomised, controlled, 3-arm, multi-centre study of neoadjuvant osimertinib as monotherapy or in combination with chemotherapy, versus SoC chemotherapy alone, for the treatment of patients with resectable…
- Trial name
- NeoADAURA (NCT04351555)
- Testing
- Osimertinib, Cisplatin, Carboplatin
- Where
- 158 sites in United States, Austria and 23 more
- Volunteers
- 358 people
- Sponsor
- AstraZeneca
Gastrinoma, Glucagonoma
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
This phase II trial studies regorafenib in treating patients with neuroendocrine tumors that have spread from the primary site (place where it started) to other places in the body.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT02259725
- Testing
- regorafenib, laboratory biomarker analysis
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- University of Southern California
Advanced Solid Tumors
A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors
The proposed clinical trial is a phase I, open-label, multi-center, dose-escalation study of ALT-803 in patients with surgically incurable advanced solid tumors: melanoma, renal cell, non-small cell lung and squamous cell head…
- Trial name
- NCT01946789
- Testing
- ALT-803
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Altor BioScience
Locally Advanced or Metastatic NSCL Cancer Stage IIIB IV
Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer
This is a Phase I, open label multicentre study of selumetinib administered orally in combination with first line chemotherapy regimens to patients with advanced/metastatic NSCLC.
- Trial name
- SELECT-3 (NCT01809210)
- Testing
- selumetinib, gemcitabine, cisplatin
- Where
- 4 sites in United Kingdom
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Lung Cancer
Auris Robotic Endoscopy System for Bronchoscopy
In this study, the performance related to the use of the novel Robotic Endoscopy Platform during bronchoscopic procedures will be evaluated.
- Trial name
- NCT03497026
- Testing
- Robotic Bronchoscopy Platform
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Auris Health, Inc.
Cancer
COVID-19 Infection Screening in Cancer Patients (NEOSCREENCOVID)
Since December 2019, outbreak of COVID-19 caused by a novel virus SARS-Cov-2 has spread rapidly around the world and became a pandemic issue.
- Trial name
- NEOSCREENCOVID (NCT04492410)
- Testing
- rapid serological test
- Where
- France
- Volunteers
- 214 people
- Sponsor
- Centre Antoine Lacassagne
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.